345 related articles for article (PubMed ID: 21425979)
21. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.
Węsierska-Gądek J; Maurer M
Curr Pharm Des; 2011; 17(3):256-71. PubMed ID: 21348827
[TBL] [Abstract][Full Text] [Related]
22. Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Palomino-Schätzlein M; Pineda-Lucena A
Methods Mol Biol; 2016; 1336():211-23. PubMed ID: 26231718
[TBL] [Abstract][Full Text] [Related]
23. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.
Łukasik P; Baranowska-Bosiacka I; Kulczycka K; Gutowska I
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802080
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
26. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
28. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinases: bridging their structure and function through computations.
De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
[TBL] [Abstract][Full Text] [Related]
30. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akin S; Babacan T; Sarici F; Altundag K
J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
[TBL] [Abstract][Full Text] [Related]
31. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
32. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M; Cataldi A; di Giacomo V
BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
[TBL] [Abstract][Full Text] [Related]
34. Green light for the cell cycle.
Inzé D
EMBO J; 2005 Feb; 24(4):657-62. PubMed ID: 15678103
[TBL] [Abstract][Full Text] [Related]
35. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
36. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
38. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
39. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]